Clinical Study to Investigate the Systemic Exposure, Safety, and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Male Volunteers

NCT02924155 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: SJP002
DRUG: Placebo

Sponsor

Samjin Pharmaceutical Co., Ltd.